Table 2 AUCs of optimized models using individual versus combined MRI features.

From: Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL

Model type

Full N = 384 pCR rate = 29.7%

HR+/HER2-N = 162 pCR rate = 14.8%

HR+/HER2+N = 60 pCR rate = 31.7%

HR-/HER2+N = 30 pCR rate = 66.7%

HR-/HER2-N = 132 pCR rate = 38.6%

FTV only

0.77 (0.73, 0.83)

0.72 (0.61, 0.84)

0.71 (0.52, 0.85)

0.67 (0.48, 0.74)

0.74 (0.64, 0.83)

BPE only

0.69 (0.62, 0.76)

0.66 (0.47, 0.73)

0.76 (0.64, 0.88)

0.75 (0.46, 0.81)

0.62 (0.50, 0.74)

SPH only

0.69 (0.62, 0.75)

0.68 (0.54, 0.81)

0.65 (0.48, 0.74)

0.73 (0.47, 0.77)

0.56 (0.49, 0.67)

LD only

0.79 (0.73, 0.85)

0.73 (0.61, 0.84)

0.78 (0.63, 0.89)

0.64 (0.49, 0.86)

0.75 (0.64, 0.83)

Combined

0.81 (0.76, 0.86)

0.83 (0.77, 0.92)

0.88 (0.79, 0.97)

0.83

0.82 (0.74, 0.91)

  1. Note —Numbers in parentheses are 95% confidence intervals.